AngioDynamics Q1 Revenue Rises 6.9% as Med Tech Growth Leads; FY2027 Outlook Reiterated

AngioDynamics (NASDAQ: ANGO) reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9% year over year, as double-digit growth in its Med Tech segment outweighed slower expansion in Med Device. The company also reiterated its full-year outlook and reported adjusted EBITDA of $5.0 million, keeping profitability and cash generation central to its fiscal 2027 plans.

Med Tech sales rose 13.2% to $39.9 million, compared with $35.3 million a year earlier, while Med Device sales increased 1.4% to $41.0 million from $40.4 million. Med Tech accounted for 49% of quarterly revenue, up from 47% in the prior-year period. Segment gross margin was 66.2% for Med Tech and 52.7% for Med Device.

Med Tech portfolio drives growth

Auryon revenue increased 14.7% to $18.9 million, marking the business’s 21st consecutive quarter of double-digit growth. AngioDynamics attributed the performance to its shift toward hospital atherectomy procedures, expansion of its customer base and early international adoption.

Mechanical thrombectomy sales rose 6.7% to $12.0 million. AlphaVac revenue climbed 37.4% to $4.5 million, while AngioVac revenue declined 5.9% to $7.5 million. Including Unifuse, whose sales fell 36.0% to $0.7 million, total thrombus management revenue increased 3.0% to $12.7 million.

The company said demand remained strong for AlphaVac and AngioVac and noted continued progress on AlphaReturn and its infective endocarditis study. Both programs have received investigational device exemption approval.

NanoKnife generated $8.3 million in sales, up 29.0%, supported by record prostate procedure volumes and demand for probes. Disposable revenue increased 24.1% to $6.7 million, while capital revenue rose 53.5% to $1.7 million. AngioDynamics said expanding reimbursement coverage following a positive Medicare decision in the previous quarter also supported adoption.

Fiscal 2027 outlook maintained

AngioDynamics reiterated fiscal 2027 net sales guidance of $336 million to $341 million, compared with $320 million in fiscal 2026. The outlook assumes Med Tech revenue growth of 12% to 15% and flat Med Device sales, with Med Tech expected to represent about half of total revenue.

The company continues to expect a full-year gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million and an adjusted loss per share of $0.29 to $0.24.

AngioDynamics ended the quarter with $34 million in cash and no debt, with additional flexibility available through its revolving credit line. It used approximately $15.3 million of cash from operations during the quarter, which the company described as consistent with historical trends. Management expects the business to generate positive operating cash flow for fiscal 2027.

Leadership transition

Eric Honroth will become president and chief executive officer and join the board effective Nov. 2, 2026, succeeding Jim Clemmer after a board-led search. Honroth has more than 20 years of leadership experience in medical devices and life sciences, including cardiovascular, endovascular, urology and oncology markets. Clemmer will remain with AngioDynamics as an executive adviser.

The company cautioned that its outlook remains subject to risks including regulatory actions, clinical-trial outcomes, competitive and pricing pressures, product acceptance, litigation, foreign-exchange movements, tariffs, inflation, labor constraints, supply-chain challenges and the availability and cost of raw materials. Execution of strategic initiatives and the company’s ability to secure product clearances or approvals could also affect results.